Balyasny Asset Management LLC Pliant Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $337,607 - $498,115	31,910 New	31,910 $343,000
Q4 2023 Feb 14, 2024	BUY	$12.85 - $19.15 $477,287 - $711,288	37,143 New	37,143 $672,000
Q2 2023 Aug 14, 2023	BUY	$18.12 - $30.56 $1.39 Million - $2.35 Million	76,863 Added 732.52%	87,356 $1.58 Million
Q1 2023 May 15, 2023	SELL	$18.73 - $36.26 $420,563 - $814,182	-22,454 Reduced 68.15%	10,493 $279,000
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $312,137 - $466,920	18,361 Added 125.88%	32,947 $636,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $111,874 - $353,418	14,586 New	14,586 $305,000

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.